SECFilings.com Executive Interview Featuring Atossa Genetics, Inc. ( NASDAQ : ATOS ), The Breast Health Company, is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented, FDA-cleared diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.
In this SECFilings.com Executive Interview we speak with CEO of Prima Biomed, a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima Biomed is an Australian listed Biotech company which is cross-listed on the NASDAQ under ticker symbol PBMD.
Disclosure: Neither SECFilings.com or any of its principals currently owns or plan to own within 72 hours of publication any shares of the stocks mentioned in this video. For a full disclaimer please visit, http://secfilings.com/disclaimer.
In this SECFilings.com Executive Interview we speak with Mr. Josh Pickus, President & CEO of Support.com, a leading provider of cloud-based services and software designed to enhance a customer's experience with technology. Support.com is a publicly traded company listed on the NASDAQ under ticker symbol SPRT.
To learn more, please visit the company website at http://www.support.com.
In this SECFilings.com Executive Interview we speak with Mr. Jim Czirr, Executive Chairman of Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer. Galectin Therapeutics is a publicly traded company listed on the NASDAQ under ticker symbol GALT.
To learn more, please visit the company website at http://www.galectintherapeutics.com.
SECFilingsTV, a leader in providing executive interviews and in-depth investment analysis, recently sat down with Beamz Interactive CEO Charlie Mollo to discuss the company's management team, recent developments and future plans to unlock value for shareholders.